BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

529 related articles for article (PubMed ID: 17629365)

  • 1. DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity.
    Buonaguro L; Devito C; Tornesello ML; Schröder U; Wahren B; Hinkula J; Buonaguro FM
    Vaccine; 2007 Aug; 25(32):5968-77. PubMed ID: 17629365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation.
    Buonaguro L; Visciano ML; Tornesello ML; Tagliamonte M; Biryahwaho B; Buonaguro FM
    J Virol; 2005 Jun; 79(11):7059-67. PubMed ID: 15890945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA prime/protein boost immunization against HIV clade C: safety and immunogenicity in mice.
    Rasmussen RA; Ong H; Kittel C; Ruprecht CR; Ferrantelli F; Hu SL; Polacino P; McKenna J; Moon J; Travis B; Ruprecht RM
    Vaccine; 2006 Mar; 24(13):2324-32. PubMed ID: 16406147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maternal immune status influences HIV-specific immune responses in pups after DNA prime protein boost using mucosal adjuvant.
    Bråve A; Johansen K; Palma P; Benthin R; Hinkula J
    Vaccine; 2008 Nov; 26(47):5957-66. PubMed ID: 18801400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Robust HIV-specific immune responses were induced by DNA vaccine prime followed by attenuated recombinant vaccinia virus (LC16m8 strain) boost.
    Shinoda K; Xin KQ; Kojima Y; Saha S; Okuda K; Okuda K
    Clin Immunol; 2006 Apr; 119(1):32-7. PubMed ID: 16458074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mucosal priming with replicative Tiantan vaccinia and systemic boosting with DNA vaccine raised strong mucosal and systemic HIV-specific immune responses.
    Huang X; Liu L; Ren L; Qiu C; Wan Y; Xu J
    Vaccine; 2007 Dec; 25(52):8874-84. PubMed ID: 18061316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY; Luo L; Wainberg MA; Li Y
    Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Intranasal priming with HIV DNA vaccine and systemic boosting with recombinant vaccinia induce vigorous immune responses: experiment with mice].
    Huang XG; Xu JQ; Ren L; Qiu C; Zhang N; Liu LX; Wan YM; Peng H; Shao YM
    Zhonghua Yi Xue Za Zhi; 2006 Nov; 86(44):3109-13. PubMed ID: 17313761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma.
    Gómez CE; Abaitua F; Rodríguez D; Esteban M
    Virus Res; 2004 Sep; 105(1):11-22. PubMed ID: 15325077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Membrane bound Indian clade C HIV-1 envelope antigen induces antibodies to diverse and conserved epitopes upon DNA prime/protein boost in rabbits.
    Rangasamy SP; Menon V; Dhopeshwarkar P; Pal R; Vaniambadi KS; Mahalingam S
    Vaccine; 2016 May; 34(21):2444-2452. PubMed ID: 27032514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes.
    McBurney SP; Young KR; Ross TM
    Virology; 2007 Feb; 358(2):334-46. PubMed ID: 17011011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical evaluation of cellular immune responses elicited by a polyvalent DNA prime/protein boost HIV-1 vaccine.
    Cristillo AD; Wang S; Caskey MS; Unangst T; Hocker L; He L; Hudacik L; Whitney S; Keen T; Chou TH; Shen S; Joshi S; Kalyanaraman VS; Nair B; Markham P; Lu S; Pal R
    Virology; 2006 Mar; 346(1):151-68. PubMed ID: 16325880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral DNA vaccination promotes mucosal and systemic immune responses to HIV envelope glycoprotein.
    Kaneko H; Bednarek I; Wierzbicki A; Kiszka I; Dmochowski M; Wasik TJ; Kaneko Y; Kozbor D
    Virology; 2000 Feb; 267(1):8-16. PubMed ID: 10648178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralizing activity and cellular immune responses induced in mice after immunization with apoptotic HIV-1/murine leukemia virus infected cells.
    Hinkula J; Walther-Jallow L; Laurén A; Mäkitalo B; Oberg M; Wahren B; Fenyö EM; Spetz AL
    Vaccine; 2009 Oct; 27(46):6424-31. PubMed ID: 19549607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype.
    Pal R; Kalyanaraman VS; Nair BC; Whitney S; Keen T; Hocker L; Hudacik L; Rose N; Mboudjeka I; Shen S; Wu-Chou TH; Montefiori D; Mascola J; Markham P; Lu S
    Virology; 2006 May; 348(2):341-53. PubMed ID: 16460776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intranasal HIV-1-gp160-DNA/gp41 peptide prime-boost immunization regimen in mice results in long-term HIV-1 neutralizing humoral mucosal and systemic immunity.
    Devito C; Zuber B; Schröder U; Benthin R; Okuda K; Broliden K; Wahren B; Hinkula J
    J Immunol; 2004 Dec; 173(11):7078-89. PubMed ID: 15557206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prime-boost immunization with DNA, recombinant fowlpox virus and VLP(SHIV) elicit both neutralizing antibodies and IFNgamma-producing T cells against the HIV-envelope protein in mice that control env-bearing tumour cells.
    Radaelli A; Bonduelle O; Beggio P; Mahe B; Pozzi E; Elli V; Paganini M; Zanotto C; De Giuli Morghen C; Combadière B
    Vaccine; 2007 Mar; 25(11):2128-38. PubMed ID: 17241705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A).
    Staats HF; Nichols WG; Palker TJ
    J Immunol; 1996 Jul; 157(1):462-72. PubMed ID: 8683152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Humoral immune responses by prime-boost heterologous route immunizations with CTB-MPR(649-684), a mucosal subunit HIV/AIDS vaccine candidate.
    Matoba N; Geyer BC; Kilbourne J; Alfsen A; Bomsel M; Mor TS
    Vaccine; 2006 Jun; 24(23):5047-55. PubMed ID: 16621185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clarification of how HIV-1 DNA and protein immunizations may be better used to obtain HIV-1-specific mucosal and systemic immunity.
    Hinkula J
    Expert Rev Vaccines; 2007 Apr; 6(2):203-12. PubMed ID: 17408370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.